Please login to your online account to display your discounted pricing

GE Healthcare rmp Protein A Sepharose™ Fast Flow Affinity Media

Designed for high-purity separation of monoclonal and polyclonal antibodies

$741.52 - $4,340.00

Specifications

Binding Capacity >Min. 22mg Human IgG/mL
Particle Size 60 to 165μm
Product Type rmp Protein A Sepharose fast flow media
For Use With (Application) For high-purity separation of monoclonal and polyclonal antibodies
Ligand Type Recombinant Protein A (E. coli)
View More Specs
Products
Catalog Number Mfr. No. Quantity Price Quantity    

45-002-974

 
ge healthcare
17513801
5mL Each for $741.52

45-002-975

 
ge healthcare
17513802
25mL Each for $2,544.48

45-002-976

 
ge healthcare
17513803
200mL Each for $4,340.00
Description & Specifications

Specifications

Binding Capacity >Min. 22mg Human IgG/mL
Particle Size 60 to 165μm
Product Type rmp Protein A Sepharose fast flow media
For Use With (Application) For high-purity separation of monoclonal and polyclonal antibodies
Ligand Type Recombinant Protein A (E. coli)
Matrix 4% Cross-Linked Agarose
pH Range 3 to 10
Stability Stable in aqueous Buffers commonly used in Protein A Chromatography
Storage Requirements 2 to 8°C

  • Non-mammalian-based media composed of recombinant Protein A coupled with Sepharose 4 Fast Flow base matrix by reductive amination
  • Coupling chemistry that minimizes leakage of protein A ligand
  • Multi-point attachment of rProtein A by chemically-stable amide bonds
  • High capacity and good pressure/flow characteristics provide for high throughput

  • Matrix: 4% cross-linked agarose
  • Average particle size: 90μm (d50V)
  • Ligand: recombinant protein A (E. coli)
  • pH Stability working range: 3 to 10
  • pH Stability cleaning-in-place: 2 to 11
  • Binding capacity/mL chromatography medium: >35mg human IgG/mL
  • Pressure/Flow specification: base matrix 150 to 250cm/hr., 100kPa, XK 50/60 column

For therapeutic applications requiring extremely pure eluate fractions of antibodies with non-exposure of antibodies to human or animal derivatives during purification process.